Back
HFA Premium Access

Differences in VWF activity in patients with von Willebrand disease type 2A versus LVAD patients with the acquired von Willebrand syndrome.

Session: Poster Session 1 - Chronic Heart Failure – Treatment
Topic: Ventricular Assist Devices
Speaker: Doctor M. Vanderheyden (Aalst, BE)
Event: Heart Failure 2018

Congress Presentation

Add to my library

Like

About the speaker

Doctor Marc Vanderheyden

Olv Hospital Aalst, Aalst (Belgium)
0 follower

67 more presentations in this session

Combined therapy with ACEI/ARB, beta-blocker, statin, antithrombotic drug and cardiovascular mortality in comorbide patients with heart failure, coronary artery disease, arterial hypertension

Access
Slides
Like
Thumbnail

Heart failure over 19 years: are we on the right way?

Access
Like
Thumbnail

B-blockers and prognosis in cardiac amyloidosis

Speaker: Doctor E. Repasos (Athens, GR)

Access
Abstract
Like
Thumbnail

Safety and efficacy of valsartan-sacubitril in a cohort of patients with symptomatic heart failure receiving small doses of ACE

Speaker: Doctor A. Ntalianis (Athens, GR)

Access
Abstract
Like
Thumbnail

Barriers and motivations to physical activity in heart failure patients; is a specific approach needed for women?

Speaker: Professor T. Jaarsma (Linkoping, SE)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 1 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Vanderheyden, Doctor E. Repasos, Doctor A. Ntalianis, Professor T. Jaarsma
Access
Like
Thumbnail

About the event

Image

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources